Bradley Merrill Thompson, Member of the Firm, will moderate a panel discussion, “Social Media & New Technology: FDA Guidance, Mobile Apps & Digitization,” at the Food and Drug Law Institute’s Annual Meeting, which runs from April 24 to 25.
Social media and new technology are directly affecting the FDA regulatory environment. Increasingly, the agency itself is using social media to disseminate important information. At the same time, the medical products industry is seeking further FDA guidance on industry use of this growing phenomenon. Social media is also part of a paradigm shift in technology that is disrupting the medical products community, including the digitization of promotional literature and the proliferation of mobile applications. In this session, experts will discuss:
- What Does/Would FDA Guidance on Social Media Really Mean?
- How Will FDA Regulate Mobile Devices and What Does the Adverse Events App RFP Mean for Stakeholders?
- Why is Digitization So Crucial to Medical Products?